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The recognition of altered immune system function in 
many chronic disease states has proven to be a pivotal 
advance in biomedical research over the past decade. 
For many metabolic and mood disorders, this altered 
immune activity has been characterized as inflamma-
tion, with the attendant assumption that the immune 
response is aberrant. However, accumulating evidence 
challenges this assumption and suggests that the im-
mune system may be mounting adaptive responses 
to chronic stressors. Further, the inordinate complex-
ity of immune function renders a simplistic, binary 
model incapable of capturing critical mechanistic in-
sights. In this perspective article, we propose alterna-
tive paradigms for understanding the role of the im-
mune system in chronic disease. By invoking allostasis 
or systems biology rather than inflammation, we can 
ascribe greater functional significance to immune me-
diators, gain newfound appreciation of the adaptive 
facets of altered immune activity, and better avoid the 
potentially disastrous effects of translating erroneous 
assumptions into novel therapeutic strategies.      
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Introduction
 Depression and metabolic disease exhibit an in-
terdependent relationship. Obesity and type 2 diabetes 
mellitus are associated with increased incidence of de-
pression, and patients with depression are at increased 
risk for the development of metabolic disease.1 Though 
this relationship is poorly understood, the presence of 
altered immune system activity in both disorders may 
provide a key pathophysiologic link. Indeed, over the 
past 2 decades, changes in immune system activity have 
been identified as a hallmark feature of many chronic 
diseases, including depression, obesity, type 2 diabetes 
mellitus, atherosclerosis, and cancer.2-6 Common chang-
es in immune function across these disorders may in 
part underlie their association in epidemiologic studies. 
These observations collectively have generated a novel 
paradigm, that of inflammation contributing to the initi-
ation and progression of chronic disease. This paradigm 
has been pivotal for capturing critical insights about the 
dynamic regulation of immune function in a variety of 
disorders. 
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 Nevertheless, use of the term inflammation in de-
pression and metabolic disease may also inadvertently 
encourage the continued use of explanatory models 
deprived of context. Specifically, the “inflammation” 
model engenders a binary understanding of biology, 
wherein inflammation is detrimental and its attenu-
ation beneficial. This construct of inflammation as a 
unitary process thus fails to account for the exquisite 
complexity of the immune system, which comprises 
multiple cell types, each with the capacity to acquire 
highly heterogeneous phenotypes in different bio-
logical contexts. Consequently, describing the role of 
inflammation rather than the immune system in de-
pression and metabolic disease may create a falsely 
comprehensive sense of understanding pathophysiol-
ogy where significant uncertainty persists. So, too, may 
it obscure important differences in immune function in 
these respective disease states. Finally, the paradigm of 
inflammation fails to distinguish between immune sys-
tem involvement and aberrant immune function, a criti-
cal distinction when identifying potential targets for 
therapeutic interventions. In the following paragraphs, 
we first describe observations that are discordant with 
the current perceived associations between depression 
or metabolic disease and inflammation. We then discuss 
the limitations of inflammation as a paradigm for de-
scribing the role of the immune system in disease states. 
Next, we suggest the potential dangers inherent in the 
conceptualization of immune function as inflammation, 
a value-laden construct that may obscure physiologic 
insights and thereby generate therapeutic interventions 
with unintended, adverse effects. Finally, we introduce 
alternative models—allostasis and systems biology—
that may facilitate a more textured understanding of 
immune regulation in metabolic and mood disorders.
Inflammation and disease: 
a dissociable association
A causal relationship between changes in immune activ-
ity and depression is supported by the high prevalence 
of depressive syndromes among patients on interferon-
α therapy, with 25% to 50% of patients on high-dose 
therapy meeting DSM-IV (Diagnostic and Statistical 
Manual of Mental Disorders [Fourth Edition]) criteria 
for major depression.7,8 Notably, many of these patients 
derive therapeutic benefit from selective serotonin 
reuptake inhibitors, offering further, indirect evidence 
that peripheral changes in cytokine exposure can alter 
central neurotransmitter signaling.9 In humans, illness 
or experimental administration of endotoxin can pro-
duce changes in mood and behavior characteristic of 
major depression.10-13 Similarly, animal studies demon-
strate the precipitation of “depressive-like” behaviors 
after endotoxin administration in association with el-
evations of individual cytokines (eg, interleukin [IL]-
1β, IL-6).11 Hodes et al further demonstrated that sus-
ceptibility to chronic stress–induced social avoidance 
in mice appeared to be mediated by excess peripheral 
IL-6 production.14 These observations are supported 
by extensive evidence of cytokine regulation of neu-
rotransmitters central to mood and behavior.10 Thus, 
primary activation of the immune system can gener-
ate many of the behavioral, affective, and biochemical 
features of major depression. In turn, major depression 
is associated with altered immune system activity, as il-
lustrated by increased circulating levels of the cytokine 
tumor necrosis factor-α (TNF-α) and IL-6.15,16 Elevated 
cytokine production is, unsurprisingly, not unique to de-
pression but also has been reported for anxiety disor-
ders including posttraumatic stress disorder.17-20 These 
findings have collectively led to the pivotal recognition 
that immune function may be altered in depression and 
related mood disorders and the growing interest in the 
use of anti-inflammatory therapies as a novel treatment 
strategy for major depression.9,20-23
 Despite these intriguing findings, dissociations be-
tween cytokine elevation and depression have been 
observed. For example, endotoxin administration to 
patients with severe depression resulted in the acute 
remission of depressive symptoms,24 and exercise aug-
mentation produced significant antidepressant effects 
in the absence of changes in serum levels of TNF-α or 
IL-6.25 Similarly, in vitro and in vivo, pharmacologic 
antidepressant treatment has resulted in either para-
doxical increases or no changes in the production of 
cytokines, including IL-6 and IL-1β.14,26-29 Further, anti-
inflammatory agents have been shown to antagonize 
the behavioral and biochemical effects of selective 
serotonin reuptake inhibitors in mice and the antide-
pressant effects of these agents in humans.30 Observed 
dissociations between peripheral and central cytokine 
levels also underscore the limitations of making infer-
ences about a local immune response on the basis of 
circulating markers.30 Notably, too, the specific cyto-
kines reported as significantly elevated in depressed 
20
Redefining immune function in chronic disease - Rubinow and Rubinow Dialogues in Clinical Neuroscience - Vol 19 . No. 1 . 2017
patients have differed across studies and may in part 
reflect the confounding effects of medical comorbidi-
ties commonly found among patients included in these 
studies. Finally, the overlap in serum cytokine levels 
between patients and controls is substantial.31 Indeed, 
in their thoughtful review, Raison and Miller conclude 
that depression is not primarily an inflammatory disor-
der though they propose that inflammation probably 
contributes to a subset of depressive presentations.31 
Nonetheless, even these more nuanced views may risk 
conceptually collapsing dynamic changes in immune 
activity to “inflammation.” This reductionist model 
could prevent more comprehensive understanding of 
underlying biology, including specificity with regard to 
cell type, time course, and, most critically, the adaptive 
and functional significance of an immune response.
 As is true for depression, obesity and type 2 diabetes 
mellitus have been associated with elevated circulating 
cytokine levels and further may be characterized by in-
creased infiltration of immune cells into metabolic tis-
sues.3,32-34 In animal models, deficiency of TNF-α or che-
mokine (C-C motif) ligand 2 (CCL2) confers protection 
from diet-induced insulin resistance,35-37 and TNF-α can 
directly inhibit insulin signaling in vitro.38,39 These and 
similar observations have led to an analogous paradigm 
of metabolic disease as a state of chronic inflammation, 
with the attendant suggestion that immune function 
is dysregulated; therefore, immunomodulatory thera-
pies may hold promise as treatment strategies. Again, 
however, the development of such treatments posits 
aberrant immune function as a driving etiologic force 
of metabolic disorders, a problematic concept for sev-
eral reasons. First, the capacity to generate insulin resis-
tance through pharmacologic cytokine exposures does 
not definitively demonstrate that dysregulated immune 
activity drives the insulin resistance associated with 
obesity. Second, an etiopathogenic role of inflammation 
is undermined by the failure to date of immune-target-
ed therapies in the treatment of metabolic disease.40,41 
Third, as in depression, changes in serum cytokine lev-
els are dissociable from the predicted metabolic pheno-
type. Thus, lipid infusion in human subjects generated 
insulin resistance in the absence of changes in circulat-
ing cytokines.42 In mice, IL-6 deficiency led to glucose 
intolerance and insulin resistance not seen in wild-type 
controls.43 In a model of diet-induced obesity, IL-6–de-
ficient mice exhibited the same metabolic phenotype as 
wild-type controls, despite attenuated leukocytosis and 
serum amyloid A-1 (SAA-1) generation.44 In parallel, 
clinical use of an IL-6 receptor (IL-6R) neutralizing an-
tibody led to metabolic dysregulation characterized by 
markedly increased weight, hypertriglyceridemia, and 
hypercholesterolemia.45 Collectively, these observa-
tions undermine existing, simplistic models that identify 
inflammation as both hallmark feature and pathogenic 
origin of metabolic and mood disorders. Moreover, they 
underscore the importance of determining not only a 
clinical syndrome but also the underlying disease, as de-
fined by a distinct pathophysiology. 
Immune alterations: adaptation and 
maladaptation
The inference that the immune system behaves aber-
rantly in metabolic disorders disregards the critical 
question of why altered immune function is observed in 
these disease states. As an alternative construct, the im-
mune system could be mounting an adaptive response 
to the chronic stress of excess energy intake; the proli-
polytic and antiadipogenic effects of TNF-α could be 
viewed as protective, antiobesity functions that may 
attenuate lipotoxicity or glucotoxicity at the cellular 
level.41 Indeed, obesity itself has been described as an 
adaptive effort to prevent lipotoxicity in extra-adipose 
tissue.46 Thus, even if one by-product of this response 
were the promotion of insulin resistance, immune-di-
rected therapies could target adaptive responses rather 
than pathogenic triggers and pose a potential for harm 
magnified by the almost inevitable compromise of host 
defense conferred by such treatments. The complexity of 
physiologic responses to stressors is well illustrated by 
glucocorticoid activity in affective disorders. Thus, it is 
generally assumed that elevated glucocorticoid release 
corresponds to the relative physiologic overwhelm con-
ferred by a stressor. This presumption, however, breaks 
down with consideration of the individual calibration of 
the hypothalamic-pituitary-adrenal (HPA) axis or the 
timing of cortisol elevation. The isolated use of serum 
cortisol levels, for example, would fail to capture the 
physiologic overwhelm of stress-dependent disorders 
like posttraumatic stress disorder, which commonly is 
associated with low cortisol levels but increased glu-
cocorticoid receptor signaling in target tissues.47,48 Fur-
ther, in striking contrast to the presumed deleterious 
effects of glucocorticoids, increased glucocorticoid ex-
posure during or immediately before acute immobili-
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zation stress was shown to protect male rats from the 
subsequent development of anxiety-like behaviors and 
spinogenesis in the basolateral amygdala.49 These latter 
findings would suggest an unequivocally adaptive role 
for glucocorticoids. This distinction between adaptive 
and dysregulated responses is not always clear and may 
evolve with greater insights into disease pathophysiol-
ogy. The possibility also exists that a single mediator 
or process may effect both adaptive and maladaptive 
changes. The evolution of insulin resistance in obesity, 
for example, could be seen as a transition point from 
allostatic load to allostatic overload, the point at which 
physiology undergoes a sustained recalibration, as de-
scribed further below; however, insulin resistance could 
well play a concurrent role in protecting cells from glu-
cose- or lipid-associated toxicity. Analogously, the phe-
nomenon of post-ischemic stroke depression occurs in 
association with increased cytokine production.50 Yet 
even as this immune activation could potentiate depres-
sion, it also might play a key role in neuronal protec-
tion and recovery from ischemic injury.51 This duality 
of benefit and harm is illustrated further by glucocor-
ticoid signaling in the hippocampus, which exerts acute, 
protective effects on neurons by inhibiting excessive 
glucose uptake but nonetheless also can contribute 
directly to neuronal death.52 Similarly, elimination of 
IL-1β or TNF reduces the pain of peripheral nerve in-
juries but markedly impairs healing,53 and both TNF-α 
and IL-6 display complex, context-dependent effects on 
learning, memory, and synaptic regulation, which may 
be beneficial (even critical) or detrimental depending 
upon context.54 
 The occurrence of adaptive and maladaptive se-
quelae also may be separated temporally. Obesity itself 
may be adaptive in certain contexts, as overeating could 
confer protective, stress-alleviating effects that contrib-
ute immediately to reproductive success, albeit at the 
expense of the individual’s long-term health.55 Thus, 
the perspective from which the biological system is ob-
served must first be defined, as the same mediators may 
appear to confer maladaptive changes with regard to 
systemic glucose metabolism or clinical symptoms but 
nonetheless continue to play protective, adaptive roles 
with regard to cellular function and survival. This dy-
namic approach to understanding adaptation reflects 
the intricate network of biologic systems involved in 
any stress response. Adaptation entails not a linear pro-
gression of events but rather extensive crosstalk among 
multiple regulatory arms, including the immune system, 
sympathetic and parasympathetic nervous systems, and 
neuroendocrine systems.56 Yet, pharmacologic therapies 
are designed specifically to target a single locus within 
this vast regulatory framework. The attendant implica-
tion, then, is that such therapies are unlikely to restore 
an optimally adaptive state but have great potential to 
disrupt these signaling networks and thereby prevent or 
impede innate, adaptive responses.
Complexity of immune responses: 
defying a binary nomenclature
One obstacle to elucidating disease pathophysiology is 
the tendency to model disease states in terms of bio-
logical markers as opposed to biological mediators. 
Whereas mediators can play complex roles, markers 
are deprived of biological context and functional sig-
nificance; they simply rise or fall, appear or disappear. 
As a result, markers fit neatly into paradigms predicat-
ed on binary or linear constructs, but the importance of 
assigning functional significance becomes increasingly 
evident as emergent data dismantle binary or linear un-
derstandings of immune function. Rather, a clear dis-
tinction between pro- and anti-inflammatory processes 
readily disappears when individual mediators and con-
textual variables are more closely examined. The dy-
namic functional properties of immune mediators are 
compellingly illustrated by prostanoid signaling. Induc-
tion of the enzyme cyclooxygenase 2 (COX-2), for ex-
ample, generates lipid mediators that evolve both early 
and late in immune cell activation and function to both 
propagate and resolve the immune response. Although 
prostaglandin E2 (PGE2) promotes vasodilation and 
neutrophil chemotaxis, it also confers suppressive ef-
fects on T-cell proliferation and activation.57 Further, 
progressive accumulation of PGE2 may be critical for 
the generation of resolvins and protectins, the lipid sig-
nals that help terminate an immune response.58 Thus, 
PGE2 exerts complex effects and cannot be reduced 
to a simple pro- or anti-inflammatory designation as 
would be required by the rubric of inflammation. 
 As noted above, the effects of an individual immune 
mediator depend on critical variables, including the 
timing and magnitude of exposure, the specific cell and 
tissue type, and the presence of concurrent signals. The 
actions of an individual mediator, therefore, can only 
be understood within a defined biological context. The 
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time-dependent nature of paracrine signaling is illus-
trated by the adipokine adiponectin, which triggers an 
initial burst of nuclear factor-κB activity and cytokine 
secretion in macrophages. Subsequent to this transient 
activation, however, adiponectin-treated macrophages 
exhibit a substantially diminished response to endo-
toxin stimulation.59 The phenomenon of macrophage 
tolerance to endotoxin similarly illustrates that the 
cellular response to a given stimulus can differ mark-
edly on the basis of previous exposure.60 Notably, too, 
endotoxin tolerance is characterized by reductions only 
in specific cytokines and can be abrogated completely 
when macrophages are pretreated with interferon-γ.61 
These observations are complemented by the recent 
demonstration that previous exposure to a stressor dra-
matically and persistently alters the gene-expression 
profile resulting from a subsequent stressor, evidence 
of a reprogrammed cellular response.62 Even the ki-
netics of biological signaling are critical, as pulsatile 
versus sustained exposures elicit different genetic ac-
tivation profiles, despite the same cumulative “dose of 
signal.”63 Further, as with PGE2, the physiologic effects 
of other immune-derived mediators are concentration-
dependent. In vitro data suggest that TNF-α diminishes 
insulin-stimulated glucose uptake at higher concentra-
tions but actually augments adipocyte glucose uptake at 
lower concentrations.64 Moreover, the metabolic effects 
of TNF-α may be divergent across different tissue types, 
as TNF-α–deficient mice exhibited reduced lipid accu-
mulation in liver but not skeletal muscle during high-
fat feeding.65 Adding an additional layer of complexity, 
the magnitude of signal exposure encompasses not only 
the concentration of a mediator but also the relative 
expression of its receptor, cellular localization of the 
receptor, and flux in postreceptor pathways, which may 
undergo continual remodeling under different biologi-
cal conditions. The heterogeneous effects of these indi-
vidual mediators find parallel in the apparent paradox 
that metabolic and mood disorders represent states of 
both heightened immune system activity and relative 
immunosuppression.66,67 Thus, an ever-growing body of 
data refuses to conform to the extant understanding of 
inflammation as a discrete, present-or-absent process. 
Instead, aggregate findings mandate a reformed frame-
work that can accommodate the innumerable vari-
ables of biological context. Such a revised framework 
is essential to restore functional relevance to otherwise 
mere markers of disease. 
Aberration versus adaptation: 
allostasis as an alternative construct to 
inflammation
The challenge then arises to develop alternative para-
digms capable of incorporating these findings that ap-
pear discordant within the current conceptual frame-
work of inflammation. One such alternative construct 
is that of allostasis, a model initially applied to cardio-
vascular physiology and hypertension and subsequently 
expanded to describe the effects of chronic stress.55,56,68 
In contradistinction to homeostasis, allostasis invokes 
continual adaptation and change rather than conserva-
tion of a single set point. Further, allostatic theory posits 
that these adaptations entail not only reactive but also 
anticipatory responses designed to optimize efficiency 
and, ultimately, survival and reproductive success.55 
Importantly, however, allostatic theory does not as-
sume that the new state of equilibrium will be identical 
to that achieved before stress. Allostatic load also can 
transition to a state of allostatic overload if the stressors 
become sufficiently chronic or the attendant energy re-
quirements exceed energy intake. In states of allostatic 
overload, maladaptive or dysregulated responses now 
become evident. Further, even the adaptive responses 
to stress, particularly with prolonged stress, may them-
selves lead to seemingly adverse consequences and 
thereby contribute to allostatic load. Thus, in contrast to 
models of homeostasis, allostasis allows for physiologic 
recalibration of the biological system and creates con-
ceptual space for adaptive responses that may result in 
new biological set points. Whereas homeostasis invokes 
linear and binary designations, allostasis is an intrinsi-
cally nonlinear model of biology.69,70 In contrast to al-
lostatic theory, the reduction of immune system activa-
tion to a unitary concept—inflammation—and selected 
biomarkers can result in missed or erroneous biologi-
cal insights and potentially dangerous translational ef-
forts. Despite its putative anti-inflammatory effects, for 
example, the selective COX-2 inhibitor rofecoxib was 
found to confer a near doubling in cardiovascular event 
rate.71 Analogously, the paradigm of oxidative stress in 
the pathogenesis of cancer and cardiovascular disease 
has led to a number of clinical trials evaluating the ef-
ficacy of antioxidants in disease prevention. Strikingly, 
however, beta carotene supplementation among smok-
ers resulted in increased risk of both lung cancer and 
cardiovascular disease.72 Such findings critically under-
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score the potential dangers of prematurely translating 
observational or in vitro findings into clinical inter-
ventions and, moreover, highlight our relative paucity 
of mechanistic insight into the pathogenesis of many 
chronic diseases. 
 A second and related model, systems biology, views 
phenotype as the highly context-dependent output of 
integrated networks of cells and signaling molecules. 
Understanding these multipathway networks requires 
measurement of many targets across multiple cell types 
under many conditions.73 The fundamental insight of 
systems biology is that a physiologic system cannot be 
understood if examined in isolation or assessed under 
only one condition, even if thousands of variables are 
quantified. As such, the same stimulus may elicit differ-
ent or opposite responses as a function of the state of 
the network. This phenomenon characterizes the func-
tioning of genetic and brain networks and has been well 
recognized in neuroscience research but is now inargu-
ably not unique to the field; as a rule, then, biological 
signals simply cannot be reliably interpreted indepen-
dent of context. 
Conclusion
Cytokine signaling is of enormous physiologic and 
pathophysiologic importance, with a vast and continu-
ally expanding spectrum of described biological effects. 
The exquisite complexity of immune system function 
and its exquisitely complex relationship to the etio-
pathogenesis of metabolic and affective disorders sim-
ply cannot be captured through reductionist terms like 
“proinflammatory.” Rather, binary and linear models 
become increasingly devoid of meaning as they fail to 
evolve with emergent findings. Whereas inflammation 
once captured previously unrecognized roles of the im-
mune system, it now promotes a physiologically inac-
curate model that at best impedes understanding and at 
worst may lead to premature and potentially destruc-
tive therapeutic strategies. Our efforts to understand 
the role of immune signaling in depression and meta-
bolic disease will be advanced only if informed by mod-
els that encourage the assignment of functional signifi-
cance to biological mediators and recognize dynamic 
changes in biological context. Thus, discrete mediators 
can and do exert different effects in the presence or 
absence of other local signals, and these effects exhibit 
variable kinetics that may result in a single mediator 
performing seemingly disparate functions at different 
time points. As conceptual frameworks inform thera-
peutic strategies, investigative questions, and the inter-
pretation of data, they must be continually reexamined 
and refined, particularly when emergent data consis-
tently challenge the existing constructs. This reformu-
lation of the immune system’s role in depression and 
metabolic disease is necessary to enable the continued 
growth of this extraordinarily promising area of investi-
gation. Even more critical, our proposed reformulation 
offers a more textured approach to biology that could 
optimize treatment strategies and help avoid those with 
the potential to do greater harm than good. o
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Redefinición del papel del sistema inmunitario 
en la enfermedad crónica dentro de la defensa 
inmune
Durante la última década, el reconocimiento de la al-
teración de la función del sistema inmune en muchas 
enfermedades crónicas ha demostrado ser un avance 
central en la investigación biomédica. En diversos tras-
tornos metabólicos y anímicos, esta actividad inmune 
alterada ha sido caracterizada como inflamación, asu-
miendo concomitantemente que la respuesta inmune es 
aberrante. Sin embargo, la evidencia acumulada desafía 
esta suposición y sugiere que el sistema inmune puede 
estar estructurando respuestas adaptativas a estresores 
crónicos. Además, un modelo simplista y binario no es 
capaz de dar cuenta de la excesiva complejidad de la 
función inmune ni hacer comprensibles los mecanismos 
internos esenciales. En este contexto, este artículo de 
perspectiva se propone entregar paradigmas alternati-
vos para la comprensión del papel del sistema inmune 
en la enfermedad crónica. Al invocar la alostasis o la 
biología de sistemas antes que la inflamación, se puede 
atribuir un mayor significado funcional a los mediado-
res inmunes, obtener una nueva apreciación de los as-
pectos adaptativos de la actividad inmune alterada, y 
evitar mejor los efectos potencialmente desastrosos de 
traducir suposiciones erróneas en nuevas estrategias te-
rapéuticas.
Vers une redéfinition du rôle du système 
immunitaire dans la maladie chronique
Ces 10 dernières années, l’identification d’une altération 
du système immunitaire dans de nombreuses maladies 
chroniques est au centre des avancées de la recherche 
biomédicale. Dans de nombreux troubles métaboliques 
ou de l’humeur, cette activité immunitaire modifiée se 
caractérise par une inflammation, ce qui suppose une 
réponse immunitaire anormale. Cette hypothèse est 
néanmoins mise en défaut car un nombre croissant d’ar-
guments suggère que le système immunitaire dévelop-
perait des réponses adaptatives aux facteurs de stress 
chroniques. De plus, un modèle simpliste, binaire, ne 
peut rendre compte de l’extraordinaire complexité de la 
fonction immunitaire et n’est pas suffisant pour en res-
tituer les mécanismes fondamentaux. Dans ce contexte, 
nous proposons dans cet article d’autres modèles pour 
comprendre le rôle du système immunitaire dans la ma-
ladie chronique. En invoquant l’allostase ou la biologie 
de systèmes plutôt que l’inflammation, nous pouvons 
accorder une plus grande importance fonctionnelle aux 
médiateurs immunitaires, réviser notre conception des 
capacités d’adaptation d’une activité immunitaire alté-
rée et mieux éviter les effets potentiellement désastreux 
d’une traduction d’hypothèses erronées en nouveaux 
traitements.
